Janux Therapeutics (JANX) EBT Margin (2021 - 2026)

Janux Therapeutics (JANX) posted quarterly EBT Margin of 1416.02% for Q1 2026, down 7.96% quarter-over-quarter from 1311.57% in Q3 2025.

Janux Therapeutics (JANX) EBT Margin (2021 - 2026) Analysis & Trends

Janux Therapeutics (JANX) has reported EBT Margin for 6 consecutive years, with 1416.02% the latest figure, recorded in Q1 2026.

In Q1 2026, EBT Margin changed N/A year-over-year to 1416.02%; the TTM figure through Mar 2026 stood at 2537.67% (up 613070.0% YoY), while the FY2025 annual figure was 1432.21%, up 263455.0% from the prior year.
EBT Margin eased to 1416.02% in Q1 2026 per JANX's latest filing, from 1311.57% in the prior quarter.
Across five years, EBT Margin topped out at 477.77% in Q4 2023 and bottomed at 77800.68% in Q3 2024.
Historically, EBT Margin has averaged 9503.19% across 5 years, with a median of 2680.08% in 2023.
Annual changes were most pronounced in 2024 — EBT Margin sank 7674212 bps — and 2025, when it surged 7648911 bps.
Janux Therapeutics' EBT Margin stood at 576.77% in 2022, then rose by 17 bps to 477.77% in 2023, then tumbled by 16184 bps to 77800.68% in 2024, then surged by 98 bps to 1311.57% in 2025, then retreated by 8 bps to 1416.02% in 2026.
Business Quant data shows JANX's EBT Margin at 1416.02% in Q1 2026, 1311.57% in Q3 2025, and 77800.68% in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	35.61%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	34.77%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	18.33%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-94.22%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	12.09%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.77%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-2.67%
10	Janux Therapeutics	984.58 Mn	984.58 Mn	-	-589.70%

Download Data